TITLE

CRUCELL/DSM SIGN LICENSING PACT WITH MITSUBISHI PHARMA

PUB. DATE
May 2005
SOURCE
Worldwide Biotech;May2005, Vol. 17 Issue 5, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on a PER. C6 cell line research license agreement signed by DSM Biologics with Japanese pharmaceutical company Mitsubishi Pharma Corp. in 2005. Benefit of the license agreement for Mitsubishi; Terms of the contract; Information on DSM Biologics.
ACCESSION #
16894850

 

Related Articles

  • MorphoSys Signs Cooperative Agreements.  // Pharmaceutical Technology;Oct2006, Vol. 30 Issue 10, p166 

    The article announces the license agreement signed by MorphoSys AG with Crucell NV and DSM Biologics. The agreement allows the former to use a cell line designed to produce clinical-grade material and develop its therapeutic human antibody program. The financial details of these agreements were...

  • News Watch.  // European Chemical News;6/6/2005, Vol. 82 Issue 2150, p25 

    Presents news briefs concerning pharmaceutical industry as of June 2005. Research agreement signed by Codexis with Bristol-Myers Squibb to improve biocatalyst activity for a new Bristol-Myers Squibb candidate; Commercial license agreement signed by Crucell and DSM Biologics with Ferring...

  • DSM Biologics and Crucell Enter Licensing Deal. Bryner, Michelle // Chemical Week;8/1/2007, Vol. 169 Issue 26, p19 

    The article reports that DSM Biologics and Crucell of Leiden, the Netherlands have entered into an agreement to license a manufacturing technology based on the companies' jointly developed PER.C6 cell line, to LFB Biotechnologies of Paris, France. LFB will use the licensed technology to develop...

  • DSM Pharmaceuticals To Double Sterile Manufacturing Capacity. Russel, Ronelle // Pharmaceutical Technology;Feb2003, Vol. 27 Issue 2, p20 

    Reports on Greenville, North Carolina-based drug company DSM Pharmaceuticals' plans to expand its sterile manufacturing capacity. Addition of five freeze dryers and a filling line to its manufacturing site in Greenville; Manufacturing capacity of the facility upon the positioning of freeze...

  • World Briefs.  // Pharmaceutical Technology;Aug2008, Vol. 32 Issue 8, p22 

    The article offers world news briefs related to pharmaceutical industry. In Asia and Pacific, NovaMed Pharmaceuticals (Shanghai) and Pfizer China has formed a partnership in the oncology area in distributing oncology products throughout mainland China. In Europe, an agreement is made between DSM...

  • DSM and Crucell license antibody technology to Sartorius.  // PharmaWatch: Biotechnology;Jul2007, Vol. 6 Issue 7, p16 

    The article reports on the licensing agreement accorded by DSM Biologics and Crucell NV with Sartorius Biotech GmbH. The two companies have agreed to a non-exclusive PER.C6 research licensing deal with Sartorius. In addition, Sartorius will use Crucell's key technology to assess monoclonal...

  • DSM & Taiyo Unveil Teavigo EGCG Licensing Agreement.  // Nutraceuticals World;Sep2014, Vol. 17 Issue 7, p21 

    The article reports on the licensing agreement established by nutritional product supplier Koninklijke DSM NV and functional ingredients manufacturer Taiyo Kagaku Co. Ltd. for DSM's Teavigo brand EGCG business.

  • Hard Work, Thorough Analysis, and Planning Raise Quality Assurance from 483 Ashes. Fellows, Lindon // Pharmaceutical Technology;Aug2003 Supplement, Vol. 27 Issue 8, p90 

    Focuses on the DSM Pharmaceuticals Inc.'s comprehensive plan to improve manufacturing processes and change the employee culture. Overview on the company's compliance problem in its acquired contract manufacturing facility; Implementation of the program, QUICK Start to Excellence; Corporate policy.

  • Contract Services' Crystal Ball. Miller, Jim // BioPharm International;Feb2003, Vol. 16 Issue 2, p22 

    Reports developments in the pharmaceutical industry as of February 2003 in the U.S. Acquisition of Magellan Laboratories by Cardinal Health; Use of electronic data capture in the clinical trials of Novartis; Plans inspection conducted by Food and Drug Administration for DSM Pharmaceuticals Inc.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics